PHARMACY News & Analysis

Our analyst weighs in on the proposed acquisition and Sigma’s capital raise.

But the tie-up could face significant hurdles, says Morningstar analysts.  

These industries are the most undervalued in the US healthcare sector, owing to potential drug pricing reforms coming out of Washington.

Australian Pharmaceutical Industries remains a buying opportunity following its $127 million acquisition of cosmetic skin and laser hair removal...

The loss of a crucial contract this week that took a 40 per cent bit out of Sigma Healthcare (ASX: SIG) points to a larger story of disruption in...